What is Leerink Partnrs’ Estimate for JANX FY2026 Earnings?

Janux Therapeutics, Inc. (NASDAQ:JANX) – Investment analysts at Leerink Partnrs reduced their FY2026 earnings per share estimates for shares of Janux Therapeutics in a note issued to investors on Tuesday, December 3rd. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings of ($6.13) per share for the year, down from their prior estimate of ($6.12). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Janux Therapeutics’ FY2027 earnings at ($5.92) EPS and FY2028 earnings at ($4.25) EPS.

A number of other research firms have also weighed in on JANX. Leerink Partners lifted their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday. UBS Group started coverage on Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research note on Thursday, November 7th. Scotiabank lifted their price objective on Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research note on Wednesday. Finally, Wedbush restated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $79.90.

Janux Therapeutics Trading Up 11.7 %

NASDAQ JANX opened at $66.84 on Thursday. The stock has a 50-day simple moving average of $49.83 and a two-hundred day simple moving average of $45.81. Janux Therapeutics has a fifty-two week low of $7.79 and a fifty-two week high of $71.25.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company’s quarterly revenue was down 82.6% on a year-over-year basis.

Insider Buying and Selling

In other news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the transaction, the insider now directly owns 3,162,851 shares in the company, valued at $132,839,742. The trade was a 3.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. bought 1,200,000 shares of the stock in a transaction dated Friday, October 18th. The shares were bought at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the completion of the acquisition, the director now owns 9,317,246 shares in the company, valued at approximately $416,946,758.50. The trade was a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 460,610 shares of company stock worth $21,583,666. Insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its holdings in Janux Therapeutics by 0.6% in the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after acquiring an additional 47,075 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Janux Therapeutics by 40.0% in the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after acquiring an additional 721,563 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares during the last quarter. Logos Global Management LP lifted its holdings in Janux Therapeutics by 400.0% in the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after acquiring an additional 600,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Janux Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after acquiring an additional 38,490 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.